Page 21 - MemoriaCIBER2019-ENG
P. 21
Transfer
One of the CIBER’s main aims is the translation of the knowledge generated by its researchers, in such a way that the results of research are implemented in protocols, services and products for the improvement of clinical practice and the quality of life of the population at large. To this end, the Technology Transfer area of the CIBER works as a liaison between our researchers and companies, private organisations, public research centers and other innovation agents to put the cooperation between them into practice, and ensure that the results of research can finally be applied.
In 2019, 16 new priority patent applications were submitted at the CIBER. In addition, 4 software were developed and 3 licence contracts were signed:
CIBER Annual report 2019 21
THEMATIC AREA
CIBERDEM CIBERER CIBERESP CIBERSAM CIBERONC
Priority patent applications
Other IPRs and software
Licences and licence options
CIBER-BBN
5
2
1
1
-
-
CIBEREHD
2
-
-
3
-
1
CIBERES
-
-
1
-
-
-
CIBEROBN
3
2
-
1
-
-
CIBERCV
-
-
-
1
-
-
CIBERFES
-
-
-
In addition, throughout 2019, the following activities and procedures were carried out, among others:
• Dozens of CDAs and MTAs were negotiated and signed.
• Support to the CIBER spin off (EpiDisease) in achieving a capital injection through a tax lease process from the company Kaudal.
• Various ongoing marketing and technology dissemination activities are maintained.
• A multitude of partnering congresses and fairs were attended such as: BioEurope, Biotech Showcase, Phar- maforum, Medica, Biofit, ASEBIO investors Forum, World Orphan Drug Congress, Kaertor Foundation Mee- ting, etc.
• Two projects were submitted to the Caixa Impulse call (CIBERES and CIBERER) with one reaching the second phase, though not chosen.
• The CIBERER area organised the two following meetings:
- Research programs for drug discovery. (together with ASEBIO, December 4) - Designation and development of orphan drugs. (October 21, Bilbao).
• Calls for valorisation and transfer projects were launched from the CIBER-BBN area. Three valorisation projects were financed, with no transfer projects being awarded.
• Lastly, since June 2019, together with the AEMPS (Spanish Agency for Medicines and Health Products), the CIBER-BBN area participates in the STARS-CSA project: Strengthening Training of Academia in Regulatory Science.
